1,347 Shares in Amgen Inc. (NASDAQ:AMGN) Acquired by Plan Group Financial LLC

Key Points

• Plan Group Financial LLC has acquired a new position in Amgen Inc., purchasing 1,347 shares valued at approximately $420,000 in the first quarter.
• Multiple large investors have increased their stakes in Amgen, with Brighton Jones LLC raising its shares by 23.5% and Ritter Daniher Financial Advisory LLC DE increasing its holdings by 66.2% during the fourth quarter.
• Amgen recently declared a quarterly dividend of $2.38 per share, yielding 3.2% on an annualized basis, with the next payment scheduled for September 12th.

Plan Group Financial LLC acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,347 shares of the medical research company's stock, valued at approximately $420,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Pinney & Scofield Inc. purchased a new stake in shares of Amgen during the fourth quarter worth $26,000. First Pacific Financial raised its position in shares of Amgen by 304.5% in the first quarter. First Pacific Financial now owns 89 shares of the medical research company's stock worth $28,000 after buying an additional 67 shares in the last quarter. Ritter Daniher Financial Advisory LLC DE raised its position in shares of Amgen by 66.2% in the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after buying an additional 51 shares in the last quarter. Heck Capital Advisors LLC purchased a new stake in shares of Amgen in the fourth quarter worth $36,000. Finally, Legacy Investment Solutions LLC raised its position in shares of Amgen by 46.9% in the fourth quarter. Legacy Investment Solutions LLC now owns 141 shares of the medical research company's stock worth $37,000 after buying an additional 45 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, SVP Rachna Khosla sold 1,500 shares of Amgen stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the transaction, the senior vice president directly owned 8,162 shares in the company, valued at approximately $2,364,368.16. This trade represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.76% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of brokerages recently issued reports on AMGN. Citigroup increased their price objective on Amgen from $305.00 to $310.00 and gave the stock a "neutral" rating in a research report on Wednesday. Erste Group Bank downgraded Amgen from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Wall Street Zen upgraded Amgen from a "buy" rating to a "strong-buy" rating in a research report on Sunday, May 18th. Morgan Stanley increased their price objective on Amgen from $330.00 to $333.00 and gave the stock an "equal weight" rating in a research report on Wednesday. Finally, William Blair reissued an "outperform" rating on shares of Amgen in a research note on Tuesday, June 24th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $307.23.

Amgen Trading Up 0.0%

Shares of NASDAQ AMGN traded up $0.03 during trading hours on Thursday, hitting $284.70. The company's stock had a trading volume of 2,588,846 shares, compared to its average volume of 2,017,625. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.88 and a current ratio of 1.31. The stock has a market cap of $153.09 billion, a price-to-earnings ratio of 23.28, a P/E/G ratio of 2.46 and a beta of 0.49. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $339.17. The business has a 50-day simple moving average of $293.20 and a 200-day simple moving average of $292.48.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, topping the consensus estimate of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The business had revenue of $9.18 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same period last year, the business posted $4.97 earnings per share. Amgen's quarterly revenue was up 9.4% compared to the same quarter last year. On average, analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 12th. Shareholders of record on Friday, August 22nd will be issued a $2.38 dividend. The ex-dividend date is Friday, August 22nd. This represents a $9.52 annualized dividend and a yield of 3.3%. Amgen's dividend payout ratio (DPR) is 77.84%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.